Article Information
History
- November 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Vivek Naranbhai1,2,6,
- Kerri J St. Denis3,
- Evan C Lam3,
- Onosereme Ofoman4,
- Wilfredo-Garcia Beltran3,4,
- Cristhian Berrios4,
- Atul K. Bhan4,
- Justin F. Gainor1,
- Alejandro B. Balazs3,
- A. John Iafrate1,4,* and
- on behalf of the CANVAX team
- 1Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA
- 2Dana-Farber Cancer Institute, Boston, MA
- 3Ragon Institute of MGH, MIT and Harvard
- 4Department of Pathology, Massachusetts General Hospital, Boston, MA
- 6Center for the AIDS Programme of Research in South Africa, Durban, South Africa
- ↵*Corresponding author:
A. John Iafrate, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, aifrate{at}partners.org
Posted November 11, 2021.
Neutralization breadth of SARS CoV-2 viral variants following primary series and booster SARS CoV-2 vaccines in patients with cancer
